A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections (especially reactivation of latent tuberculosis), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.
麻豆原创 Analysis and Insights: Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创
The global Tumor Necrosis Factor (TNF) Inhibitor Drugs market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The market growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF).
Report Includes
This report presents an overview of global market for Tumor Necrosis Factor (TNF) Inhibitor Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Tumor Necrosis Factor (TNF) Inhibitor Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Tumor Necrosis Factor (TNF) Inhibitor Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tumor Necrosis Factor (TNF) Inhibitor Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Tumor Necrosis Factor (TNF) Inhibitor Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., Novartis International AG, Pfizer, Inc. and Merck & co., Inc., etc.
By Company
AbbVie Inc.
Amgen Inc.
Johnson & Johnson Services, Inc.
UCB S.A.
Novartis International AG
Pfizer, Inc.
Merck & co., Inc.
Segment by Type
Humira
Enbrel
Remicade
Simponi/Simponi Aria
Cimzia
Biosimilars
Segment by Application
Rheumatoid Arthritis
Psoriasis
Psoriatic Arthritis
Crohn鈥檚 Disease
Ulcerative Colitis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Hidradenitis Suppurativa
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Tumor Necrosis Factor (TNF) Inhibitor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Necrosis Factor (TNF) Inhibitor Drugs companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumor Necrosis Factor (TNF) Inhibitor Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Humira
1.2.3 Enbrel
1.2.4 Remicade
1.2.5 Simponi/Simponi Aria
1.2.6 Cimzia
1.2.7 Biosimilars
1.3 麻豆原创 by Application
1.3.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriasis
1.3.4 Psoriatic Arthritis
1.3.5 Crohn鈥檚 Disease
1.3.6 Ulcerative Colitis
1.3.7 Ankylosing Spondylitis
1.3.8 Juvenile Idiopathic Arthritis
1.3.9 Hidradenitis Suppurativa
1.3.10 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Perspective (2018-2029)
2.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Growth Trends by Region
2.2.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Dynamics
2.3.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Trends
2.3.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Drivers
2.3.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Challenges
2.3.4 Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Tumor Necrosis Factor (TNF) Inhibitor Drugs by Players
3.1.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Players (2018-2023)
3.1.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Tumor Necrosis Factor (TNF) Inhibitor Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue in 2022
3.5 Global Key Players of Tumor Necrosis Factor (TNF) Inhibitor Drugs Head office and Area Served
3.6 Global Key Players of Tumor Necrosis Factor (TNF) Inhibitor Drugs, Product and Application
3.7 Global Key Players of Tumor Necrosis Factor (TNF) Inhibitor Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Breakdown Data by Type
4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted 麻豆原创 Size by Type (2024-2029)
5 Tumor Necrosis Factor (TNF) Inhibitor Drugs Breakdown Data by Application
5.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size (2018-2029)
6.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type
6.2.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Type (2018-2029)
6.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application
6.3.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Application (2018-2029)
6.4 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country
6.4.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size (2018-2029)
7.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type
7.2.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Type (2018-2029)
7.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application
7.3.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Application (2018-2029)
7.4 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country
7.4.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size (2018-2029)
8.2 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type
8.2.1 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2018-2023)
8.2.2 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2024-2029)
8.2.3 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Type (2018-2029)
8.3 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application
8.3.1 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2018-2023)
8.3.2 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2024-2029)
8.3.3 China Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size (2018-2029)
9.2 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type
9.2.1 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Type (2018-2029)
9.3 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application
9.3.1 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Application (2018-2029)
9.4 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Region
9.4.1 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.1.5 AbbVie Inc. Recent Developments
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Details
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.2.4 Amgen Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.2.5 Amgen Inc. Recent Developments
11.3 Johnson & Johnson Services, Inc.
11.3.1 Johnson & Johnson Services, Inc. Company Details
11.3.2 Johnson & Johnson Services, Inc. Business Overview
11.3.3 Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.3.4 Johnson & Johnson Services, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.3.5 Johnson & Johnson Services, Inc. Recent Developments
11.4 UCB S.A.
11.4.1 UCB S.A. Company Details
11.4.2 UCB S.A. Business Overview
11.4.3 UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.4.4 UCB S.A. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.4.5 UCB S.A. Recent Developments
11.5 Novartis International AG
11.5.1 Novartis International AG Company Details
11.5.2 Novartis International AG Business Overview
11.5.3 Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.5.4 Novartis International AG Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.5.5 Novartis International AG Recent Developments
11.6 Pfizer, Inc.
11.6.1 Pfizer, Inc. Company Details
11.6.2 Pfizer, Inc. Business Overview
11.6.3 Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.6.4 Pfizer, Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.6.5 Pfizer, Inc. Recent Developments
11.7 Merck & co., Inc.
11.7.1 Merck & co., Inc. Company Details
11.7.2 Merck & co., Inc. Business Overview
11.7.3 Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Introduction
11.7.4 Merck & co., Inc. Revenue in Tumor Necrosis Factor (TNF) Inhibitor Drugs Business (2018-2023)
11.7.5 Merck & co., Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AbbVie Inc.
Amgen Inc.
Johnson & Johnson Services, Inc.
UCB S.A.
Novartis International AG
Pfizer, Inc.
Merck & co., Inc.
听
听
*If Applicable.